English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduSmith is a nationally recognized academic radiologist with expertise in body and oncologic imaging, clinical trials and imaging research and the application of artificial intelligence (AI) in imaging and medicine.
Tag: Pediatric Oncology
Scientists find core regulatory circuit controlling identity of aggressive leukemia
Scientists at St. Jude Children’s Research Hospital and Dana-Farber Cancer Institute found a small set of proteins that maintain anaplastic large cell lymphoma (ALCL) identity, representing potential future therapeutic targets.
Five Questions Parents Should Ask Their Child’s Oncologist About Participating in a Clinical Trial
When children undergo cancer treatment, they may be offered the chance to participate in a clinical trial. Clinical trials can provide access to new, groundbreaking therapies in a safe and controlled environment.
Hackensack Meridian Children’s Health Hospitals Earn Top Ranking for Third Year in a Row in U.S. News & World Report’s 2023-24 Best Children’s Hospitals List
Hackensack Meridian Health, New Jersey’s largest, most comprehensive hospital network, is proud to announce that the Hackensack Meridian Joseph M. Sanzari and K. Hovnanian Children’s Hospitals – filed jointly under a single program – are ranked #1 in New Jersey for the third year in a row, and #10 in the Mid-Atlantic Region in the U.S. News & World Report Best Children’s Hospitals 2023-23 Rankings.
Hackensack University Medical Center Investigators Present Pioneering Research at Annual Pediatric Cancer Meeting
Researchers from Hackensack Meridian Children’s Health at Joseph M. Sanzari Children’s Hospital at Hackensack University Medical Center presented seven studies at the American Society of Pediatric Hematology/Oncology (ASPHO) Conference in Fort Worth in May.
St. Jude scientists to receive coveted awards at AACR annual meeting
The American Association of Cancer Research (AACR) will honor two investigators from St. Jude Children’s Research Hospital for their research contributions. Melissa Hudson, M.D., director of the Cancer Survivorship Division and Jun J. Yang, Ph.D., vice-chair of Pharmacy and Pharmaceutical Sciences
Combination therapy overcomes BET inhibitor resistance
St. Jude Children’s Research Hospital scientists developed a combination therapy for a leukemia subtype harboring rearrangements in the KMT2A gene. The approach overcomes the cancer’s drug resistance, without adding toxicity. The study appears in Proceedings of the National Academy of Science.
St. Jude expands patient education resource on childhood cancer
This free online resource of information and education for families facing childhood and adolescent cancer has a truly global reach.
International Collaboration to Improve Cancer Care in Sub-Saharan Africa Focuses on Resources for Children’s Cancers
NCCN is working on new NCCN Harmonized Guidelines™ for Sub-Saharan Africa, in collaboration with the African Cancer Coalition (ACC), the American Cancer Society (ACS), and the Clinton Health Access Initiative (CHAI). The organizations are part of Allied Against Cancer, a global multi-sector effort to improve resource-stratified access to life-saving cancer care in Sub-Saharan Africa.
Rhombic lip implicated in origins of high-risk medulloblastoma
Scientists from St. Jude Children’s Research Hospital found that group 3 and 4 medulloblastoma arise from the rhombic lip, knowledge that may help improve research models and therapeutic development.
St. Jude Comprehensive Cancer Center receives Merit Extension Award from NCI
The St. Jude Comprehensive Cancer Center award extends its current $35 million, five-year Cancer Center Support Grant (CCSG) for an additional two years.
New NCCN Guidelines Analyze Evidence for Cancer Type Found Almost Exclusively in Children
National Comprehensive Cancer Network publishes first-ever complete medical guidelines for a pediatric solid tumor, so children everywhere receive the best care based on the latest research. NCCN Guidelines for Wilms Tumor shares information for earlier, safer diagnosis and treatment in effort to reduce disparities; doctors warn of late diagnosis as a possible impact from the COVID-19 pandemic.
CHOP Researchers Find NTRK Fusions More Common than Expected in Pediatric Tumors
In a large study of pediatric cancer patients, researchers from Children’s Hospital of Philadelphia (CHOP) have analyzed the frequency, fusion partners, and clinical outcome of neurotrophic tyrosine receptor kinase (NTRK) fusions, which are clinical biomarkers that identify patients suitable for treatment with FDA-approved TRK inhibitors. The researchers found that NTRK fusions are more common in pediatric tumors and also involve a wider range of tumors than adult cancers, information that could help prioritize screening for NTRK fusions in pediatric cancer patients who might benefit from treatment with TRK inhibitors.
Cardioprotective Drug Prevents Severe Cardiac Events in Children Undergoing Chemotherapy for Acute Myeloid Leukemia
The cardioprotective drug dexrazoxane preserved cardiac function in pediatric patients undergoing chemotherapy for acute myeloid leukemia (AML) without compromising overall patient survival and potentially improving it, according to a new study by researchers at Children’s Hospital of Philadelphia (CHOP). The results suggest dexrazoxane should be considered for cardioprotection in all pediatric patients undergoing standard chemotherapy for AML.